[News] NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer
21:50 EDT 26 Jun 2012 | The Lancet
On June 27, 2012, NICE published guidance recommending erlotinib as an option for the treatment of EGFR tyrosine kinase (EGFR-TK) mutation-positive advanced or metastatic non-small-cell lung cancer (NSCLC).
Original Article: [News] NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer
More From BioPortfolio on "[News] NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
